Adenocyte announced that iGan Partners led the first close of the company’s $10 million financing round to support the expansion of its pancreatic cancer early detection platform, LINFU. The funding will be used to accelerate clinical and commercial growth while advancing the company’s proprietary cytological sampling technology across pancreatic, breast, and prostate cancer applications.
The company said its LINFU system has already entered clinical use for screening high-risk pancreatic cancer patients. The outpatient procedure takes approximately 30 minutes and is generally reimbursed through Medicare and many commercial insurance plans using existing CPT billing codes. The platform also utilizes FDA-cleared technology components.
According to the announcement, Adenocyte’s patented LINFU technology combines microbubble injection with proprietary low-intensity non-focused ultrasound to safely release epithelial cells for cytological analysis. The platform is designed to identify pancreatic precancer and very early-stage cancer in high-risk populations, including individuals with pancreatic cysts, family histories of pancreatic cancer, or BRCA mutations.
The company highlighted several milestones achieved to date, including initial clinical deployment at multiple U.S. endoscopy centers where more than 150 patient procedures have already been completed successfully. Adenocyte also presented findings from its first 90 high-risk asymptomatic patients screened with LINFU at the United States and Canadian Academy of Pathology annual meeting. The company said the study demonstrated 100% specimen adequacy and specificity while detecting four previously unsuspected neoplasia cases, including a T1N0 adenocarcinoma that was not identified using EUS, MRI, or FNA.
Adenocyte also established a collaboration with Quest Diagnostics to provide national laboratory services for processing LINFU enhanced pancreatic cytology samples through Quest and AmeriPath laboratories in Tampa, Florida. The company added that a growing number of pancreatic centers are preparing to adopt LINFU screening programs over the coming quarters as commercial expansion efforts ramp up in 2026.
Sam Ifergan, Founder and Managing Partner of iGan Partners, said the firm believes Adenocyte’s platform addresses one of the biggest challenges in pancreatic cancer treatment by enabling earlier detection when intervention may still be curative.
Adenocyte is headquartered in Israel with operations based in Haifa and Jerusalem. The company said its preclinical testing was conducted at the Technion Preclinical Research Authority with support from the Israel Innovation Authority and the Gedalia Doron Research Fund at the Israel Cancer Association.
KEY QUOTES:
“At iGan Partners, we invest in clinically important platforms that can deliver practical, measurable impact. Pancreatic cancer is one of the deadliest cancers specifically because it is detected too late. Adenocyte’s LINFU platform offers a reimbursable, scalable way to find this disease earlier, when treatment can be curative, and it is already in use at leading U.S. centers. We are proud to support Mark and the Adenocyte team as they bring LINFU to many more patients.”
Sam Ifergan, Founder and Managing Partner, iGan Partners
“We are impressed by Sam Ifergan and the iGan team’s understanding of and dedication to the advancement of disruptive, life-saving medical technology, and are excited about our partnership.”
Dr. Mark Rutenberg, Founder And CEO, Adenocyte
